Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Clinical trial NCT05861271 · RECRUITING

Trial details

NCT number: NCT05861271
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Stage I

Start date: 2023-06-01
Primary completion: 2026-07-01
Enrollment: 1008

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.